AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02768909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey & Physical Exam
Description: 2. Perform a oriented survey for risk factors and a complete physical exam.
Study NCT02768909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-ray
Description: Perform anteroposterior chest X-ray
Study NCT02768909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest X-ray
Description: Perform anteroposterior chest X-ray
Study NCT02768909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sputum Samples
Description: Sputum samples for Ziehl Neelsen smear and Culture in L-J.
Study NCT02768909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sputum Samples
Description: Sputum samples for Ziehl Neelsen smear and Culture in L-J.
Study NCT02768909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Follow Up 5 days after beginning of Tx.
Description: Patients will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment.
Study NCT02768909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Follow Up 15 days after beginning of Tx.
Description: Patients will be asked to come 15 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment.
Study NCT02768909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Follow Up 30 days after beginning of Tx.
Description: Patients will be asked to come 30 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment.
Study NCT02768909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Follow Up 60 days after beginning of Tx.
Description: Patients will be asked to come 60 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment.
Study NCT00822809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10
Study NCT00822809 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Catumaxomab
Description: Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10
Study NCT00822809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 25 mg premedication
Study NCT04361474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Nasal
Description: Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
Study NCT04361474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.
Study NCT03320512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3
Description: P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
Study NCT03320512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3+
Description: In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.
Study NCT03320512 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control participants will receive the standard of care for receiving a prescription for PrEP.
Study NCT03526640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The BioSentry Tract Sealant System
Description: The BioSentry Tract Sealant System consists of a delivery system and a coaxial adapter with Bio-Seal™ plug. The hydrogel plug is deployed in the tract created by the lung biopsy needle and self-expands upon contact with moist tissue.
Study NCT01363505 — intervention group
Intervention type: DEVICE
Intervention: BARD® Intra-abdominal Pressure monitor
Description: monitor linked to foley catheter that is able to measure pressure inside bladder
Study NCT03844971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer assisted arthrocentesis of
Description: Under general anesthesia : patients specific preoperative prefabricated surgical guide will be used intraoperative for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction
Study NCT03401489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PACESETTER
Description: Patients will be given a Viaca electronic pill tray \& blue-toothed UA-767 Plus BT BP device and the PACESETTER app installed on their smart phone for automatic relay of BP data. The Vaica tray emits a blinking light for 30 minutes when it is time to take the meds. If the compartment is not opened and emptied, an intermittent chime ensues for 30 minutes. If the compartment is not opened and emptied, the subject /caregiver receives an automated SMS. PACESETTERs will be given a questionnaire. Responses will be used to generate personalized motivational \& reinforcement messages guided by self-determination theory constructs of competence \& autonomous regulation. In addition to personalized messages, PACESETTERs will receive text messages 2 times per week on HTN/stroke facts, importance of med adherence, and tips on expressing questions/concerns with a physician. We will calculate medication possession ratios, on all subjects' HTN medications at each evaluation.
Study NCT04091867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sEphB4-HSA with chemotherapy
Description: sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
Study NCT02490072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline(Saline 0.9%)
Study NCT00712959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)
Description: 0.5 ml, IM
Study NCT04091867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
Study NCT04091867 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 6930 cGy IMRT starting D15-D18
Study NCT04468750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesiotape
Description: During the rehabilitation program, all patients with GHS had kinesiotaping three times a week.
Study NCT01154725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education and rehabilitation
Description: Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.
Study NCT01154725 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: habitual patient education
Description: habitual patient education
Study NCT00712959 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)
Description: 0.5 mL, IM
Study NCT03911583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CG)
Description: The control group does not receive these notifications (PUSH)
Study NCT03911583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate physical activity group (MPA)
Description: The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
Study NCT03911583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intense physical activity group (IPA)
Description: The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
Study NCT01370083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tongue Pressure Profile Training
Description: 60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.
Study NCT01370083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tongue-Pressure Strength-and-Accuracy Training
Description: 60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
Study NCT03319394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The First Twenty
Description: The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.
Study NCT03319394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
Study NCT02043522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioisotope
Description: One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
Study NCT02343926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMIGLIPTIN LS15-0444
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT02343926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT02343926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT01520792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol (drug)
Description: Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
Study NCT03994640 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cannabis Cream
Description: Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles
Study NCT02343926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT03954873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 20% (w/v) glucose infusion for regulating plasma glucose
Study NCT03994640 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Topical, bilteral skin application of placebo cream with self-massage of masseter muscles
Study NCT03406156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered via intravenous infusion
Study NCT02769871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroimages of stroke
Description: Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
Study NCT03954873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Actrapid (insulin) for lowering plasma glucose
Study NCT03406156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Administered via intravenous infusion
Study NCT03406156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: The venetoclax dose was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg. Venetoclax was continued for a total duration of up to 53 weeks, including the 5-week ramp-up schedule. Participants were instructed to take venetoclax tablets with a meal and water at approximately the same time each day. Venetoclax tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
Study NCT04035187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fast itraconazole tablet
Description: 100mg dose
Study NCT04035187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medium itraconazole tablet
Description: 100mg dose
Study NCT04035187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: slow itraconazole tablet
Description: 100mg dose
Study NCT04035187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral itraconazole solution
Description: 100mg dose
Study NCT03954873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Actrapid (insulin) for lowering plasma glucose
Study NCT05920616 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
Study NCT05920616 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultra-High Resolution Computed Tomography (CT) Scan
Description: Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.
Study NCT05358912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressor Agent
Description: Patients will receive vasopressor agents according to Surviving Sepsis Campaign Guidelines 2021
Study NCT05358912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressor Agent
Description: Patients will receive vasopressor agents according to Surviving Sepsis Campaign Guidelines 2021
Study NCT05358912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: Patients will receive crystalloid solutions according to Surviving Sepsis Campaign Guidelines 2021
Study NCT05358912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid Solutions
Description: Patients will receive crystalloid solutions according to Surviving Sepsis Campaign Guidelines 2021
Study NCT05358912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive Blood Pressure Monitoring
Description: Invasive blood pressure monitoring will be performed through an intra-arterial cannula placed in the radial artery. Philips Intellivue mx 500 monitors will be used for bedside monitoring.
Study NCT05358912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Blood Pressure Monitoring
Description: Invasive blood pressure monitoring will be performed through an intra-arterial cannula placed in the radial artery. Philips Intellivue mx 500 monitors will be used for bedside monitoring.
Study NCT05358912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-Abdominal Pressure Monitoring
Description: IAP will be measured indirectly by monitoring the pressure in the bladder.~Bladder pressure will be measured through an indwelling Foley catheter every twelve hours. Twenty-five mL of sterile normal saline will be injected in each measurement and readings will be recorded with a pressure transducer.
Study NCT05358912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Abdominal Pressure Monitoring
Description: IAP will be measured indirectly by monitoring the pressure in the bladder.~Bladder pressure will be measured through an indwelling Foley catheter every twelve hours. Twenty-five mL of sterile normal saline will be injected in each measurement and readings will be recorded with a pressure transducer.
Study NCT05358912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Perfusion Pressure
Description: APP will be calculated with the following formula: (Mean arterial pressure) - (Intra-abdominal Pressure)
Study NCT00472641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone/Geodon
Description: Ziprasidone/Geodon
Study NCT03583866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 7 days of Candesartan (16mg/day)
Study NCT03583866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 days of Placebo
Study NCT02039570 — intervention group
Intervention type: OTHER
Intervention: Transvaginal scan
Description: transvaginal scan conducted using duplex ultrasonography
Study NCT02662465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
Study NCT02631694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Intake of propranolol pill (40 milligram)
Study NCT02631694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: Intake of propranolol pill (40 milligram)
Study NCT02631694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intake of placebo pill (40 milligram)
Study NCT02631694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbon dioxide
Description: Inhalation of 35% carbon dioxide
Study NCT03463876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR 1210+apatinib
Description: SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
Study NCT03103061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Coronary vasodilator
Study NCT02631694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon dioxide
Description: Inhalation of 35% carbon dioxide
Study NCT02631694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Compressed air
Description: Inhalation of air
Study NCT00860977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Description: oral valacyclovir 500mg twice daily
Study NCT00860977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
Study NCT01981369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous sedation with dexmedetomidine
Study NCT01981369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous sedation with propofol